O	0	10	Prevention
O	11	13	of
O	14	20	breast
O	21	27	cancer
O	28	37	treatment
O	37	38	-
O	38	45	induced
B-condition	46	50	bone
I-condition	51	55	loss
O	56	58	in
B-eligibility	59	72	premenopausal
I-eligibility	73	78	women
O	79	86	treated
O	87	91	with
B-intervention	92	102	zoledronic
I-intervention	103	107	acid
O	107	108	:
O	109	114	Final
O	115	116	5
O	116	117	-
O	117	121	year
O	122	129	results
O	130	134	from
O	135	138	the
O	139	149	randomized
O	149	150	,
O	151	157	double
O	157	158	-
O	158	163	blind
O	163	164	,
O	165	172	placebo
O	172	173	-
O	173	183	controlled
O	184	191	ProBONE
O	192	194	II
O	195	200	trial
O	200	201	.

O	202	215	Premenopausal
O	216	221	women
O	222	231	receiving
O	232	244	chemotherapy
O	245	247	or
O	248	257	endocrine
O	258	267	treatment
O	268	271	for
O	272	277	early
O	278	284	breast
O	285	291	cancer
O	292	295	are
O	296	298	at
O	299	308	increased
O	309	313	risk
O	314	317	for
O	318	324	cancer
O	325	334	treatment
O	335	342	induced
O	343	347	bone
O	348	352	loss
O	353	354	(
O	354	359	CTIBL
O	359	360	)
O	360	361	.

O	362	365	The
O	366	369	aim
O	370	372	of
O	373	376	the
O	377	387	randomized
O	387	388	,
O	389	395	double
O	395	396	-
O	396	401	blind
O	402	409	ProBONE
O	410	412	II
O	413	418	trial
O	419	422	was
O	423	425	to
O	426	437	investigate
O	438	445	whether
O	446	447	a
O	448	449	2
O	449	450	-
O	450	454	year
O	455	463	adjuvant
O	464	473	treatment
O	474	478	with
O	479	480	4
O	481	483	mg
O	484	495	intravenous
O	496	506	zoledronic
O	507	511	acid
O	512	513	(
O	513	516	ZOL
O	516	517	)
O	518	523	every
O	524	525	3
O	526	532	months
O	533	539	versus
B-control	540	547	placebo
O	548	553	would
O	554	561	prevent
O	562	567	CTIBL
O	568	573	after
O	574	575	a
O	576	580	five
O	580	581	-
O	581	585	year
O	586	592	period
O	592	593	.

B-intervention-participants	594	600	Thirty
I-intervention-participants	600	601	-
I-intervention-participants	601	604	one
O	605	607	of
O	608	611	the
O	612	614	34
O	615	627	participants
O	628	630	in
O	631	634	the
O	635	638	ZOL
O	639	642	arm
O	643	646	and
B-control-participants	647	653	thirty
I-control-participants	653	654	-
I-control-participants	654	658	four
O	659	661	of
O	662	665	the
O	666	668	36
O	669	681	participants
O	682	684	in
O	685	688	the
O	689	696	placebo
O	697	700	arm
O	701	705	were
O	706	714	followed
O	714	715	-
O	715	717	up
O	718	720	to
O	721	724	the
O	725	726	5
O	726	727	-
O	727	731	year
O	732	737	visit
O	738	741	and
O	742	751	completed
O	752	755	the
O	756	761	study
O	762	764	as
O	765	772	planned
O	772	773	.

O	774	777	The
O	778	785	changes
O	786	788	in
O	789	793	Bone
O	794	798	Mass
O	799	806	Density
O	807	808	(
O	808	811	BMD
O	811	812	)
O	813	817	were
O	818	826	assessed
O	827	829	at
O	830	838	baseline
O	839	842	and
O	843	847	each
O	848	853	visit
O	854	859	after
O	860	869	treatment
O	870	880	initiation
O	880	881	.

O	882	887	After
B-outcome	888	890	24
I-outcome	891	897	months
O	897	898	,
B-outcome	899	902	BMD
I-outcome	903	905	at
I-outcome	906	909	the
I-outcome	910	916	lumbar
I-outcome	917	922	spine
O	923	929	showed
O	930	931	a
B-iv-cont-mean	932	933	2
I-iv-cont-mean	933	934	.
I-iv-cont-mean	934	935	9
I-iv-cont-mean	935	936	%
O	937	945	increase
O	946	948	in
O	949	957	patients
O	958	965	treated
O	966	970	with
O	971	974	ZOL
O	975	977	vs
O	977	978	.
O	979	980	a
B-cv-cont-mean	981	982	7
I-cv-cont-mean	982	983	.
I-cv-cont-mean	983	984	1
I-cv-cont-mean	984	985	%
O	986	994	decrease
O	995	997	in
O	998	1005	placebo
O	1005	1006	-
O	1006	1013	treated
O	1014	1026	participants
O	1027	1035	compared
O	1036	1038	to
O	1039	1047	baseline
O	1048	1049	(
O	1049	1050	p
O	1051	1052	<
O	1053	1054	0
O	1054	1055	.
O	1055	1058	001
O	1058	1059	)
O	1059	1060	.

O	1061	1065	Over
O	1066	1069	the
B-outcome	1070	1072	60
I-outcome	1072	1073	-
I-outcome	1073	1078	month
O	1079	1084	study
O	1085	1091	period
O	1091	1092	,
O	1093	1095	we
O	1096	1101	found
O	1102	1103	a
O	1104	1112	decrease
O	1113	1115	of
B-iv-cont-mean	1116	1117	2
I-iv-cont-mean	1117	1118	.
I-iv-cont-mean	1118	1119	2
I-iv-cont-mean	1119	1120	%
O	1121	1123	vs
O	1123	1124	.
B-cv-cont-mean	1125	1126	7
I-cv-cont-mean	1126	1127	.
I-cv-cont-mean	1127	1128	3
I-cv-cont-mean	1128	1129	%
O	1130	1132	in
O	1133	1136	the
B-outcome	1137	1140	BMD
I-outcome	1141	1143	at
I-outcome	1144	1147	the
I-outcome	1148	1154	lumbar
I-outcome	1155	1160	spine
O	1161	1163	in
O	1164	1172	patients
O	1173	1182	receiving
O	1183	1186	ZOL
O	1187	1190	and
O	1191	1198	placebo
O	1199	1211	respectively
O	1212	1213	(
O	1213	1214	p
O	1215	1216	<
O	1217	1218	0
O	1218	1219	.
O	1219	1222	001
O	1222	1223	)
O	1223	1224	.

O	1225	1229	Over
O	1230	1233	the
O	1234	1236	60
O	1236	1237	-
O	1237	1242	month
O	1243	1248	study
O	1249	1255	period
O	1255	1256	,
O	1257	1260	BMD
O	1261	1263	in
O	1264	1267	the
O	1268	1275	placebo
O	1276	1279	arm
O	1280	1286	showed
O	1287	1288	a
O	1289	1299	continuous
O	1300	1308	decrease
O	1309	1311	at
O	1312	1315	all
O	1316	1321	sites
O	1322	1323	(
O	1323	1324	p
O	1325	1326	<
O	1327	1331	0001
O	1331	1332	)
O	1332	1333	,
O	1334	1341	whereas
O	1342	1350	patients
O	1351	1358	treated
O	1359	1363	with
O	1364	1367	ZOL
O	1368	1375	reached
O	1376	1384	baseline
B-outcome	1385	1388	BMD
I-outcome	1388	1389	-
I-outcome	1389	1395	values
I-outcome	1396	1398	at
I-outcome	1399	1402	the
I-outcome	1403	1410	femoral
I-outcome	1411	1415	neck
I-outcome	1416	1419	and
I-outcome	1420	1425	total
I-outcome	1426	1429	hip
O	1429	1430	.

O	1431	1433	In
O	1434	1441	ProBone
O	1442	1444	II
O	1444	1445	,
O	1446	1447	a
O	1448	1449	2
O	1449	1450	-
O	1450	1454	year
O	1455	1464	treatment
O	1465	1469	with
O	1470	1473	ZOL
O	1474	1475	4
O	1476	1478	mg
O	1479	1490	intravenous
O	1491	1496	every
O	1497	1498	3
O	1499	1505	months
O	1506	1515	prevented
O	1516	1522	cancer
O	1523	1532	treatment
O	1533	1540	induced
O	1541	1545	bone
O	1546	1550	loss
O	1551	1553	in
O	1554	1567	premenopausal
O	1568	1573	women
O	1574	1578	with
O	1579	1585	breast
O	1586	1592	cancer
O	1593	1596	and
O	1597	1607	maintained
O	1608	1611	the
O	1612	1615	BMD
O	1616	1618	up
O	1619	1621	to
O	1622	1623	3
O	1624	1629	years
O	1630	1634	post
O	1634	1635	-
O	1635	1644	treatment
O	1644	1645	.
